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Abstract
Alpha-1-antitrypsin (AAT) or serine protease inhibitor A1 (SERPINA1) is an important serine protease inhibitor in hu-
mans. The main physiological role of AAT is to inhibit neutrophil elastase (NE) released from triggered neutrophils,
with an additional lesser role in the defense against damage inflicted by other serine proteases, such as cathepsin G
and proteinase 3. Although there is a reported association between AAT polymorphism and different types of cancer,
this association with hematological malignancies (HM) is, as yet, unknown. We identified AAT phenotypes by
isoelectric focusing (in the pH 4.2-4.9 range) in 151 serum samples from patients with HM (Hodgkins lymphomas,
non-Hodgkins lymphomas and malignant monoclonal gammopathies). Healthy blood-donors constituted the control
group (n = 272). The evaluated population of patients as well as the control group, were at Hardy-Weinberg equilib-
rium for the AAT gene (2 = 4.42, d.f.11, p = 0.96 and 2 = 4.71, d.f.11, p = 0.97, respectively). There was no differ-
ence in the frequency of deficient AAT alleles (Pi Z and Pi S) between patients and control. However, we found a
significantly higher frequency of PiM1M1 homozygote and PiM1 allele in HM patients than in control (for phenotype:
f = 0.5166 and 0.4118 respectively, p = 0.037; for allele: f = 0.7020 and 0.6360 respectively, p = 0.05). In addition,
PiM homozygotes in HM-patients were more numerous than in controls (59% and 48%, respectively, p = 0.044).
PiM1 alleles and PiM1 homozygotes are both associated with hematological malignancies, although this is consid-
ered a functionally normal AAT variant.
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Hematological malignancies are clinically and bio-
chemically diverse disorders of unknown etiology and
characterized by the disproportionate proliferation of one
clone of B and/or T cells.
Alpha-1-antitrypsin (AAT) is a highly polymorphic
plasma glycoprotein (53 kD), synthesized in hepatocytes
(Koj et al., 1978) and subsequently secreted into the plas-
ma. It is also produced in smaller quantities by alveolar
macrophages, circulating monocytes (Mornex et al., 1986)
and in lung-derived epithelial cells (Cichy et al., 1997).
AAT, also called serine proteinase inhibitor A1 (SERPI-
NA1), is the archetypal extracellular serpin (SERine
Proteinase INhibitor).
The target proteinases of AAT originate from the
azurophilic granules of polymorphonuclear neutrophils,
which, in turn, contain three serine proteinases, elastase,
cathepsin G and proteinase 3. These proteinases participate
in lysosomal bacterial digestion and neutrophil migration
through the extracellular matrix at the sites of inflamma-
tion. The main physiological role of AAT is to inhibit
neutrophil elastase (NE) in the lower respiratory tract, so as
to protect the connective tissue against NE released from
triggered neutrophils (Travis and Salvesen, 1983), with a
lesser role in defending against damage by other serine pro-
teinases, such as cathepsin G (Duranton et al., 1998) and
proteinase 3 (Rao et al., 1991).
The AAT protein is encoded by the protease inhibitor
(Pi) locus on chromosome 14q31-32.3. Through the tech-
nique of isoelectric focusing, about 100 genetic variants of
AAT have been identified to date.
The most common alleles are the M variants, which
are subdivided into six M subtypes, homozygous or hetero-
zygous for the M1, M2, M3 and M4 alleles. When M vari-
ants are inherited in homozygous or heterozygous form,
AAT serum levels are supposed to be normal (Brantly et
al., 1988). The common variants that lead to AAT plasma
deficiency (AATD) are Z and S, which could result in
early-onset chronic obstructive pulmonary diseases, these
including emphysema and chronic bronchitis, as well as
liver disease, expressed as neonatal cholestasis, that may
give rise to juvenile cirrhosis or a slowly progressive liver
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disease in adults. Thus, individuals who are homozygous
for AATD alleles can develop liver or lung diseases. Never-
theless, AATD heterozygotes, which have inherited one
normal allele, have sufficient amounts of AAT and are
therefore less prone to diseases.
Furthermore, AAT polymorphism was also investi-
gated in various malignant diseases. It has been docu-
mented that AAT deficiency is associated with the in-
creased risk involved with several types of cancer, namely
lung cancer (Yang et al., 1999, 2008; Topic et al., 2006),
liver cancer (Propst et al., 1994), bladder cancer
(Benkmann et al., 1987), colorectal cancer (Yang et al.,
2000), and gall bladder adenocarcinoma (Callea et al.,
1982b). To our knowledge, there are only a few studies
which have investigated the association of AAT polymor-
phism with hematological malignancies. In studies by
Ananthakrishanan et al. (1979) and Callea et al. (1982a),
the, increased incidence of deficient Z and S alleles among
patients with paraproteinemias and malignant lymphoma
was evident. Therefore, the exact role of AAT variants as a
risk factor in hematological malignancies remains un-
known. Our intention was to investigate AAT polymor-
phism in patients with hematological malignancies, in par-
ticular lymphomas.
In order to evaluate the distribution of Pi phenotypes
and PiM subtypes, we performed Pi phenotyping on
healthy blood donors and patients with Hodgkins lympho-
mas, non-Hodgkins lymphomas and malignant monoclonal
gammopathies. The patient group consisted of 151 patients
(119 males and 32 females, aged between 21 and 69), with
Hodgkins lymphomas (HL, n = 26), non-Hodgkins lym-
phomas (NHL, n = 35) and malignant monoclonal gam-
mopathies (MMG, n = 90), and which had been admitted to
the Institute of Oncology and Radiology of Serbia and the
Military Medical Academy, Belgrade.
Diagnosis and typisation of malignant lymphomas
was made by histological examination of biopsied material
stained by HE and/or the MGG technique, with additional
immunohistochemical determination of at least LCA, CD3,
CD5, CD10, CD20, CD23 and CD45. Additional immuno-
histochemistry was carried out as required. Malignant
monoclonal gammopathies were revealed with monoclonal
immunoglobulin or Bence Jones protein in serum and/or
urine by electrophoresis and immunofixation.
The control group consisted of 272 healthy blood-
donors without any type of malignancies (221 males and 51
females, aged 20-65). Investigated populations, both con-
trol and patents, were proportional to the ethnic back-
ground.
The protocol was approved by local research ethics
committees, and informed consent was obtained from all
the participants.
Pi phenotyping of serum samples was carried out by
isoelectric focusing (pH range 4.2-4.9) according to the
method by Kishimoto et al. (1990). By using such a narrow
range of pH for gradient and self-casted 0.2 mm thin poly-
acrylamide gels, we could clearly distinguish the three M
subtypes (M1, M2 and M3). Before focusing serum, sam-
ples were pretreated by dithioerythritol.
The 2 test was used to assess whether control and pa-
tient groups were in Hardy-Weinberg equilibrium for the
AAT gene. Investigation of differences in the frequencies
of AAT phenotypes and alleles, as well as the frequency of
M homozygote and M heterozygote between patients and
controls, were investigated, also by using the 2 test (2 x 2
contingency table). The Fisher exact test was used when
n < 5. P values of < 0.05 were considered significant. For
statistical analysis, we used STATISTICA 6.0® software.
There was no deviation from Hardy-Weinberg equi-
librium in either study group (2 = 4.71, d.f.11, p = 0.97 for
control; 2 = 4.42, d.f.11, p = 0.96 for HM patients).
The differences in distribution of Pi phenotypes and
gene frequencies between patients and control are shown in
Table 1. The M1 homozygote was significantly more fre-
quent in HM patients than in controls (f = 0.5166 and
f = 0.4118 respectively, p = 0.037). In addition, the M1 al-
lele was more frequent in patients than in control group
(f = 0.7020 and 0.6360 respectively, p = 0.05). Further-
more, we evaluated differences in distribution among the M
subtypes, the homozygotes (M1M1, M2M2, and M3M3)
and heterozygotes (M1M2, M1M3 and M2M3). This re-
vealed there were more M homozygotes in patients than in
the control group (59% and 48%, respectively, p = 0.044).
Although PiM subtypes are not linked to any disease,
there are some studies in which a distinct association be-
tween a lowered M3 allele and monoclonal gammopathies
and acute myeloid leukemia has been observed (Jelic et
al.,1996; Janardhana and Propert, 1990).
It is generally accepted that AATD phenotypes are
clinically important due to a firm linkage with liver and
lung diseases. Several mutations of AAT are associated
with low plasma level of AAT and the most common are Z
and S variants. To date, few studies have been dedicated to
examining the correlation of AAT polymorphism with he-
matological malignancies, although two such studies have
described the association between the PiMZ phenotype and
paraproteinemias and lymphomas (Ananthakrishanan et
al., 1979; Callea et al.,1982a). These authors presented the
hypothesis that AAT could be included in the development
of immunopathological disorders. In our study, no differ-
ences were apparent in the frequency of AATD phenotypes
(MZ and MS) or alleles (Z and S) between HM patients and
healthy individuals. Our results are in accordance with
those gathered by El-Akawi et al. (2008) which showed
that in all breast cancer patients, the normal allele (PiMM)
was homozygous, though this is not the case for PiZ or PiS.
Nevertheless, a borderline difference between patients and
control in the distribution of PiM subtypes was manifest.
There were more PiM1M1 homozygotes and M1 alleles in
patients than in control individuals. Furthermore, we dis-
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covered higher PiM homozygote (M1M1, M2M2 and
M3M3) frequency in patients than in controls (59% and
48% respectively, p = 0.044). Thus, PiM heterozygotes
(M1M2, M1M3 and M2M3) were more abundant in
healthy individuals than in patients (52% and 41% respec-
tively, p = 0.044).
The mechanism that leads to an increase in PiM
homozygosity in hematological malignancies is unknown.
We believe that enlightenment on this will contribute to a
better understanding of HM pathogenesis. Although it is
considered that PiM subtypes are not related to diseases, we
will present a hypothesis regarding their connection with
HM.
The discrepancy regarding PiM homozygosity be-
tween patients and control could be due to certain advan-
tages arising from PiM heterozygotes in healthy individu-
als. Two articles have been published which reported
quantitative differences between PiM homozygotes and
PiM heterozygotes. From the Beckman study (Beckman
and Beckman, 1980), it was shown that in PiM homozy-
gotes the AAT serum level was lower than in PiM heterozy-
gotes. In the study by Oakeshott et al.,(1985), the func-
tional activity of AAT was defined in a large sample group
of blood donors, this including serum elastase inhibitory
capacity. In their study it appeared that the values for
elastase inhibitory capacity, concentration of AAT and
their ratio (ratio = EIC/AAT) in PiM homozygotes were
lower than in PiM heterozygotes. According to Gibson et
al. (1983), it was shown that the lung function in females
was greater in PiM heterozygotes than in PiM homozygotes
or in any other Pi phenotypes with low 1-antitrypsin activ-
ity. Based on these studies, we assumed that increased PiM
homozygote frequency in patients with HM may be due to
their slightly reduced concentration and functional activity,
which could lead to perturbation of the protease-antipro-
tease balance. In fact, imbalance between neutrophil
elastase and alpha-1-antitrypsin is generally considered to
be the cause of tissue damage, thereby creating a favorable
tissue environment for carcinogens and tumor progression
(Sun and Yang, 2004). Having in mind that PiM homozy-
gotes with hematological malignancies are not really AAT
deficient, as is the case of PiZ homozygotes, we can assume
that an unknown risk factor (or factors) may be involved in
the development of protease-antiprotease imbalance.
To conclude, the higher frequency of PiM1 homozy-
gotes and PiM1 allele in patients with hematological malig-
nancies could be a consequence of a so far unknown
association between the main serine protease inhibitor and
hematological malignancies.
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